ResearcherJiangsu Province HospitalNo recent work listed

Jin Feng

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2014: 1 paper

Papers 1

HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Co-author DOI 10.18632/oncotarget.2200 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zekuan Xu · 1 shared paper, 2014 · strength 0.04
- Paper HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. DOI 10.18632/oncotarget.2200 ↗
Guoxin Zhang · 1 shared paper, 2014 · strength 0.04
- Paper HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. DOI 10.18632/oncotarget.2200 ↗
Bin Wang · 1 shared paper, 2014 · strength 0.04
- Paper HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. DOI 10.18632/oncotarget.2200 ↗
Zheng Chen · 1 shared paper, 2014 · strength 0.04
- Paper HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. DOI 10.18632/oncotarget.2200 ↗
Wenjie Zhang · 1 shared paper, 2014 · strength 0.04
- Paper HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. DOI 10.18632/oncotarget.2200 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.